Pfeffingen, Switzerland

Alexander Hagenbach

This inventor holds 1 USPTO granted patent. Top assignee: Sandoz Gmbh. Active years: 1987.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alexander Hagenbach. Retrieved from https://idiyas.com/inventor/alexander-hagenbach

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 1987

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Alexander Hagenbach

Introduction

Alexander Hagenbach is a notable inventor based in Pfeffingen, Switzerland. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as dopaminergic and analgesic agents. His work has implications for the treatment of various neurological and pain-related conditions.

Latest Patents

Hagenbach holds a patent for "Indolophenanthridines useful as dopaminergic and analgesic agents." This patent, specifically for the compound 4,6,6a,7,8,12b-hexahydro-indolo[4,3-ab]phenanthridines, showcases his innovative approach to creating effective therapeutic agents. The patent highlights the potential of these compounds in medical applications.

Career Highlights

Throughout his career, Alexander Hagenbach has been associated with Sandoz GmbH, a prominent company in the pharmaceutical industry. His work at Sandoz has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research and development.

Collaborations

Hagenbach has worked alongside esteemed colleagues such as Hans J. Wuthrich and Max P. Seiler. These collaborations have enriched his research and have led to advancements in the understanding of dopaminergic and analgesic compounds.

Conclusion

Alexander Hagenbach's contributions to medicinal chemistry and his innovative patent demonstrate his commitment to advancing healthcare solutions. His work continues to influence the development of new therapeutic agents that can improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…